Coccidioidomycosis Outlook Highlights The Limits Of Regulatory Incentives
Executive Summary
The US FDA heard a lot about the structural, medical and especially financial barriers facing coccidioidomycosis, or Valley fever, drug development soon after the agency refused to qualify the rare fungal infection for priority review voucher incentives.